Quality of life in a real-world cohort of advanced breast cancer patients: a study of the SONABRE Registry
-
Published:2020-08-20
Issue:12
Volume:29
Page:3363-3374
-
ISSN:0962-9343
-
Container-title:Quality of Life Research
-
language:en
-
Short-container-title:Qual Life Res
Author:
Claessens Anouk K. M., Ramaekers Bram L. T., Lobbezoo Dorien J. A., van Kampen Roel J. W., de Boer Maaike, van de Wouw Agnes J., Dercksen M. Wouter, Geurts Sandra M. E., Joore Manuela A., Tjan-Heijnen Vivianne C. G.ORCID
Abstract
Abstract
Purpose
We aimed to evaluate quality of life (QoL) using the European Quality of Life Five-Dimensions questionnaire (EQ-5D-3L) in a real-world cohort of Dutch advanced breast cancer (ABC) patients. Secondary, we reported differences in QoL between subgroups of patients based on age, comorbidity, tumor-, and treatment characteristics, and assessed the association of duration of metastatic disease and time to death with QoL.
Methods
ABC patients who attended the outpatient clinic between October 2010 and May 2011 were asked to fill out the EQ-5D-3L questionnaire. Patient-, disease-, and treatment characteristics were obtained from the medical files. Health-utility scores were calculated. Subgroups were described and compared for utility scores by parametric and non-parametric methods.
Results
A total of 92 patients were included with a median utility score of 0.691 (Interquartile range [IQR] 0.244). Patients ≥ 65 years had significantly worse median utility scores than younger patients; 0.638 versus 0.743, respectively (p = 0.017). Moreover, scores were significantly worse for patients with versus those without comorbidity (medians 0.620 versus 0.725, p = 0.005). Utility scores did not significantly differ between subgroups of tumor type, type of systemic treatment, number of previous palliative treatment(s), or number or location of metastatic site(s). The remaining survival was correlated with utility scores (correlation coefficient (r) = 0.260, p = 0.0252), especially in the subgroup < 65 years (r = 0.340, p = 0.0169), whereas there was no significant correlation with time since metastatic diagnosis (r = − 0.106, p = 0.3136).
Conclusion
Within this real-world cross-sectional study, QoL was significantly associated with age, comorbidity, and remaining survival duration. The observation of a lower QoL in ABC patients, possibly indicating the last period of life, may assist clinical decision-making on timing of cessation of systemic antitumor therapy.
Funder
ZonMw Maastricht Universitair Medisch Centrum F. Hoffmann-La Roche
Publisher
Springer Science and Business Media LLC
Subject
Public Health, Environmental and Occupational Health
Reference56 articles.
1. Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 68(6), 394–424. https://doi.org/10.3322/caac.21492. 2. Ruiterkamp, J., Ernst, M. F., de Munck, L., van der Heiden-van der Loo, M., Bastiaannet, E., van de Poll-Franse, L. V., et al. (2011). Improved survival of patients with primary distant metastatic breast cancer in the period of 1995–2008 A nationwide population-based study in the Netherlands. Breast Cancer Research and Treatment, 128(2), 495–501. 3. Noone, A., Howlader, N., Krapcho, M., Miller, D., Brest, A., Yu, M., et al. (2018). SEER Cancer Statistics Review 1975 - 2015. based on November 2017 SEER data submission, posted to SEER webiste April 18. Bethesda, MD: National Cancer Insitute. 4. Cardoso, F., Spence, D., Mertz, S., Corneliussen-James, D., Sabelko, K., Gralow, J., et al. (2018). Global analysis of advanced/metastatic breast cancer: Decade report (2005–2015). The Breast, 39, 131–138. https://doi.org/10.1016/j.breast.2018.03.002. 5. Kramer, J. A., Curran, D., Piccart, M., de Haes, J. C., Bruning, P., Klijn, J., et al. (2000). Identification and interpretation of clinical and quality of life prognostic factors for survival and response to treatment in first-line chemotherapy in advanced breast cancer. European Journal of Cancer, 36(12), 1498–1506.
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|